NCT03151057 2024-03-12
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
Clinical Trials
5 trialsNCT01088048 2021-03-18
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 1 Completed
NCT01796470 2020-06-02
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT02603445 2020-02-24
Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL
Novartis
Phase 1 Completed
NCT01838434 2018-01-30
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed